Literature DB >> 32329858

Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.

J-W Ji1, Y-D Zhang, Y-J Lai, C-G Huang.   

Abstract

OBJECTIVE: Methyltransferase-like 3 (Mettl3), one of "writers" for N6-methyladenosine RNA methylation is determined to participate in a variety of cell biological functions. However, the functions of Mettl3 on tumor growth of glioma remain unknown. Here, we conducted a research to explore the contribution of Mettl3 in the progression of glioma. PATIENTS AND METHODS: To detect the expression level of RNAs, quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed. To access the relative level of proteins, Western blot was conducted. The proliferative ability of glioma cells was detected by CCK-8 assay and colony formation assay. The migration and invasion of glioma cells were determined by wound healing assay and transwell invasion assay.
RESULTS: The expression of Mettl3 was significantly downregulated in tumor tissues compared to the adjacent normal tissues. The downregulation of Mettl3 led to the enhancement of glioma cell proliferation, migration, and invasion in vitro, and promoted the tumor growth of glioma cells in vivo. In addition, further investigation confirmed that Mettl3 plays critical roles in the development of glioma by targeting PI3K/Akt pathway.
CONCLUSIONS: Our study proves that Mettl3 plays a critical role in the proliferation, migration, and invasion of glioma cells by inactivating PI3K/Akt signaling pathway, providing a novel mechanism of glioma tumorigenesis and raising a new target for the treatment of glioma.

Entities:  

Year:  2020        PMID: 32329858     DOI: 10.26355/eurrev_202004_20848

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Discovery of novel targets and mechanisms of MEK inhibitor Selumetinib for LGG treatment based on molecular docking and molecular dynamics simulation.

Authors:  Dongdong Zhang; Tieying Zhang; Jianbo Zhu; Jin Li
Journal:  J Mol Model       Date:  2022-05-06       Impact factor: 1.810

2.  Decreased RNA m6A methylation enhances the process of the epithelial mesenchymal transition and vasculogenic mimicry in glioblastoma.

Authors:  Min Tao; Xiaoyu Li; Lei He; Xiaoming Rong; Hongxuan Wang; Jingrui Pan; Zijing Lu; Xiaoni Zhang; Ying Peng
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

3.  [Atorvastatin inhibits malignant behaviors and induces apoptosis in human glioma cells by up-regulating miR-146a and inhibiting the PI3K/Akt signaling pathway].

Authors:  Y Cui; S Fan; D Pan; Q Chao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

Review 4.  The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer.

Authors:  Zhouhan Xu; Jun Jiang; Shun Wang
Journal:  Cell Mol Neurobiol       Date:  2022-09-15       Impact factor: 4.231

5.  Molecular mechanism of m6A methylation of circDLC1 mediated by RNA methyltransferase METTL3 in the malignant proliferation of glioma cells.

Authors:  Quansheng Wu; Xiaofeng Yin; Wenbo Zhao; Wenli Xu; Laizhao Chen
Journal:  Cell Death Discov       Date:  2022-04-26

Review 6.  The Progression of N6-methyladenosine Study and Its Role in Neuropsychiatric Disorders.

Authors:  Chunguang Lei; Qingzhong Wang
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

Review 7.  The evolving landscape of N6-methyladenosine modification in the tumor microenvironment.

Authors:  Yunru Gu; Xi Wu; Jingxin Zhang; Yuan Fang; Yutian Pan; Yongqian Shu; Pei Ma
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

8.  The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma.

Authors:  Fei Li; Ping Zhang
Journal:  Comput Math Methods Med       Date:  2021-11-19       Impact factor: 2.238

9.  lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2.

Authors:  Wenjun Mao; Shengfei Wang; Ruo Chen; Yijun He; Rongguo Lu; Mingfeng Zheng
Journal:  Open Med (Wars)       Date:  2022-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.